SML2302
Vildagliptin
≥98% (HPLC)
别名:
Vildagliptin, (2S)-1-[[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile, LAF-237, NVP-LAF237, (S)-1-(((1R,3R,5R,7S)-3-hydroxyadamantan-1-yl)glycyl)pyrrolidine-2-carbonitrile
登录查看公司和协议定价
所有图片(1)
选择尺寸
变更视图
50 MG
$133.00
250 MG
$473.00
About This Item
推荐产品
方案
≥98% (HPLC)
表单
powder
旋光性
[α]/D -81 to -91°, c = 0.1 in methanol
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
N#C[C@H]1N(CCC1)C(CN[C@@](C[C@]2([H])C3)(C[C@@](C2)([H])C4)C[C@@]34O)=O
InChI
1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16+,17-/m0/s1
InChI key
SYOKIDBDQMKNDQ-NHMCJKAESA-N
正在寻找类似产品? 访问 产品对比指南
应用
Vildagliptin has been used:
- as a dipeptidyl peptidase-4 (DPP4) inhibitor to study its effects on endoplasmic reticulum (ER) pathway under diabetic conditions[1]
- in pharmacological inhibition to investigate the kinetics of transposable element (TE) desilencing and confirm its dependence on DPF-3 (a P-granule-localized N-terminal dipeptidase) enzymatic activity[2]
- to study its electrochemical properties and determination in biological fluid and drug forms[3]
生化/生理作用
Vildagliptin ia a selective inhibitor of dipeptidyl peptidase 4 (DPP4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones that are released in response to a meal. By preventing GLP-1 and GIP inactivation, GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas.
Vildagliptin may participate in lipid metabolism. It plays a key role in attenuating postprandial hypertriglyceridemia, reducing serum triglycerides, apolipoprotein B, and blood total cholesterol levels. Vildagliptin is used in diabetes mellitus type 2 (DM2) therapy and may also possess vasculoprotective properties. Vildagliptin also helps to improve mitochondrial dysfunction caused by diabetes.[4]
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
其他客户在看
Rajani Kanth Gudipati et al.
Molecular cell, 81(11), 2388-2402 (2021-04-15)
Small RNA pathways defend the germlines of animals against selfish genetic elements, yet pathway activities need to be contained to prevent silencing of self genes. Here, we reveal a proteolytic mechanism that controls endogenous small interfering (22G) RNA activity in
Alberto Palazzuoli et al.
Heart failure reviews, 23(3), 325-335 (2018-01-24)
Heart failure (HF) is a common complication in patients with type 2 diabetes and it is closely associated with high morbidity and mortality rate. The incidence of cardiovascular events in patients with diabetes is related to high levels of glycemia
Michał Wiciński et al.
International journal of molecular sciences, 21(7) (2020-03-29)
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Glucagon-like peptide-1)
Firstly electrochemical examination of vildagliptin at disposable graphite sensor: Sensitive determination in drugs and human urine by square-wave voltammetry
Altunkaynak Y, et al.
Microchemical Journal, Devoted to the Application of Microtechniques in All Branches of Science, 170, 106653-106653 (2021)
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury.
Pongpan Tanajak et al.
The Journal of endocrinology, 236(2), 69-84 (2017-11-17)
Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) effects on cardiac ischemia/reperfusion (I/R) injury are unclear. Unlike SGLT2-i, dipeptidyl peptidase 4 inhibitors (DPP4-i) have shown effective cardioprotection in cardiac I/R injury. We aimed to investigate whether SGLT2-i reduces myocardial dysfunction and myocardial injury
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
